Add Boehringer Ingelheim to HitGen’s drug discovery collaboration list

HitGen has formed a drug discovery research collaboration with Boehringer Ingelheim to identify novel small-molecule leads.

Boehringer Ingelheim is joining a long list of biopharma companies and research institutes lining up for HitGen’s drug discovery capabilities centered around DNA-encoded library (DEL).

Like its previous collaborations, Chengdu, China-based HitGen did not disclose specific therapeutic areas of interest or financial details, but said it will receive upfront payments and be eligible for milestone payments.

During the synthesis process, HitGen adds building blocks to novel chemical structures through a technique called “Split & Pool,” then encodes each compound with a known sequence of DNA. The company said on its website that it has produced over 800 DELs with all together 85 billion DNA-encoded compounds.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: China’s HitGen bags new drug discovery deal with Aduro

The compounds are screened simultaneously against a target, and only those with strong affinity to the protein will be advanced into the next phase, where the structures of selected chemicals will be identified via DNA sequencing.

With that technology, HitGen has formed many drug discovery partnerships with the industry and academics. In 2017 alone, before the BI deal, it entered into research collaborations with Takeda, Aduro, Leo Pharma, the Scripps Research Institute, Pfizer, Merck & Co. and Cancer Research U.K.

HitGen currently has more than 20 projects in research, with two in preclinical candidate compound generation and one in lead generation. It offers different partnering models, can design and synthesize DELs on specific requests, screen its DELs against targets provided by a partner and work with partners to co-develop lead candidates or out-license projects.

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.